US grant for Immunomedics' breast cancer agent:
This article was originally published in Clinica
Executive Summary
Immunomedics has received a US grant to test an imaging peptide for diagnosing breast cancer. The company has developed a peptide labelled with the nuclear isotope technetium-99m that binds to a receptor which is increased in breast and several other cancers. The Phase I study is expected to demonstrate the peptide's ability to image human breast cancer.